Outcomes after biologic initiation among patients with severe asthma and normal lung function in the CHRONICLE study
Open Access
- 7 January 2026
- journal article
- research article
- Published by Springer Nature in Respiratory Research
- Vol. 27 (1) , 5
Abstract
A subset of patients with severe asthma (SA) has normal lung function, defined by a pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1) ofKeywords
Funding Information
- AstraZeneca United States
This publication has 9 references indexed in Scilit:
- Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe AsthmaThe Journal of Allergy and Clinical Immunology: In Practice, 2022
- Tezepelumab in Adults and Adolescents with Severe, Uncontrolled AsthmaNew England Journal of Medicine, 2021
- The CHRONICLE Study of US Adults with Subspecialist-Treated Severe Asthma: Objectives, Design, and Initial ResultsPragmatic and Observational Research, 2020
- Characterization of Severe Asthma WorldwideChest, 2020
- Randomised controlled trials in severe asthma: selection by phenotype or stereotypeEuropean Respiratory Journal, 2018
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trialThe Lancet, 2016
- Mepolizumab Treatment in Patients with Severe Eosinophilic AsthmaNew England Journal of Medicine, 2014
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthmaEuropean Respiratory Journal, 2013
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001